Please use this identifier to cite or link to this item:
Title: Cannabinoids and Parkinson's Disease
Authors: García-Arencibia, Moisés 
García, Concepción
Fernández-Ruiz, Javier
UNESCO Clasification: 320507 Neurología
Keywords: Cannabinoids
Cannabinoid signaling system
CB1 receptors
CB2 receptors
Basal ganglia, et al
Issue Date: 2009
Publisher: 1871-5273
Journal: CNS and Neurological Disorders - Drug Targets 
Abstract: Cannabinoid-based medicines have been proposed as clinically promising therapies in Parkinsons disease (PD), given the prominent modulatory function played by the cannabinoid signaling system in the basal ganglia. Supporting this pharmacological potential, the cannabinoid signaling system experiences a biphasic pattern of changes during the progression of PD. Thus, early and presymptomatic stages, characterized by neuronal malfunctioning but little evidence of neuronal death, are associated with desensitization/downregulation of CB1 receptors. It was proposed that these losses may be part of the pathogenesis itself, since they can aggravate different cytotoxic insults which are controlled in part by cannabinoid signals, mainly excitotoxicity but also oxidative stress and glial activation. By contrast, intermediate and, in particular, advanced stages of parkinsonism characterized by a profound nigral degeneration and occurrence of major parkinsonian symptoms (e.g. bradykinesia), are associated with upregulatory responses of CB1 receptors, possibly CB2 receptors too, and the endocannabinoid ligands for both receptor types. This would explain the motor inhibition typical of this disease and the potential proposed for CB1 receptor antagonists in attenuating the bradykinesia typical of PD. In addition, certain cannabinoid agonists have been proposed to serve as neuroprotective molecules in PD, given their well-demonstrated capability to reduce excitotoxicity, calcium influx, glial activation and, in particular, oxidative injury that cooperatively contribute to the degeneration of nigral neurons. However, the potential of cannabinoid-based medicines in PD have been still scarcely studied at the clinical level despite the existence of solid and promising preclinical evidence. Considering the relevance of these preclinical data, the need for finding treatments for motor symptoms that may be alternative to classic dopaminergic replacement therapy, and the lack of efficient neuroprotective strategies in PD, we believe it is of major interest to develop further studies that allow the promising expectations generated for these molecules to progress from the present preclinical evidence towards a real clinical application.
ISSN: 1871-5273
DOI: 10.2174/187152709789824642
Source: CNS and Neurological Disorders - Drug Targets [ISSN 1871-5273], v. 8, p. 432-439
Appears in Collections:Artículos
Show full item record


checked on May 19, 2024


checked on May 23, 2024

Page view(s)

checked on Jul 29, 2023

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.